Literature DB >> 21767715

Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae.

George A Pankey1, Deborah S Ashcraft.   

Abstract

Polymyxin B (PB) plus meropenem (MER) or rifampin (RIF) was tested by Etest® method and time-kill assay (TKA) against 14 genetically unique clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. PB + MER: Etest, 43% synergy; TKA, 64% synergy. Concordance between methods was 79%. For PB + RIF: Etest, 21% synergy; TKA, 100% synergy. Concordance between methods was 21%.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21767715     DOI： 10.1016/j.diagmicrobio.2011.05.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  15 in total

1.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

2.  Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Authors:  Valerio Del Bono; Daniele Roberto Giacobbe; Anna Marchese; Andrea Parisini; Carmen Fucile; Erika Coppo; Valeria Marini; Antonio Arena; Alexandre Molin; Antonietta Martelli; Angelo Gratarola; Claudio Viscoli; Paolo Pelosi; Francesca Mattioli
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

3.  Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae.

Authors:  Brandon Kulengowski; Jeffrey J Campion; David J Feola; David S Burgess
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

4.  Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.

Authors:  John K Diep; David M Jacobs; Rajnikant Sharma; Jenna Covelli; Dana R Bowers; Thomas A Russo; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.

Authors:  Thea Brennan-Krohn; Katherine A Truelson; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

7.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 8.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

9.  Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.

Authors:  M P Freire; L C Pierrotti; H H C Filho; K Y Ibrahim; A S G K Magri; P R Bonazzi; L Hajar; M P E Diz; J Pereira; P M Hoff; E Abdala
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-30       Impact factor: 3.267

10.  Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.

Authors:  Cornelius J Clancy; Liang Chen; Jae H Hong; Shaoji Cheng; Binghua Hao; Ryan K Shields; Annie N Farrell; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.